C4 Therapeutics, Inc.CCCCEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CCCC Q3 2025 Key Financial Metrics
Revenue
$11.2M
Gross Profit
N/A
Operating Profit
$-34.4M
Net Profit
$-32.2M
Gross Margin
N/A
Operating Margin
-306.4%
Net Margin
-286.4%
YoY Growth
-26.9%
EPS
$-0.44
Financial Flow
C4 Therapeutics, Inc. Q3 2025 Financial Summary
C4 Therapeutics, Inc. reported revenue of $11.2M for Q3 2025, with a net profit of $-32.2M (-286.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $11.2M |
|---|---|
| Net Profit | $-32.2M |
| Gross Margin | N/A |
| Operating Margin | -306.4% |
| Report Period | Q3 2025 |
C4 Therapeutics, Inc. Annual Revenue by Year
C4 Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $35.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $35.6M |
| 2023 | $20.8M |
| 2022 | $31.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $3.0M | $12.0M | $15.4M | $5.2M | $7.2M | $6.5M | $11.2M |
| YoY Growth | 14.3% | -19.2% | 350.7% | 38.7% | 58.8% | 138.2% | -46.2% | -26.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $376.5M | $398.4M | $381.1M | $376.1M | $349.6M | $319.5M | $296.5M | $265.5M |
| Liabilities | $130.3M | $140.1M | $134.0M | $133.4M | $133.6M | $124.4M | $122.5M | $111.1M |
| Equity | $246.1M | $258.3M | $247.1M | $242.7M | $216.0M | $195.1M | $174.1M | $154.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-24.0M | $-18.1M | $-5.0M | $-24.1M | $-17.9M | $-33.3M | $-12.1M | $-31.2M |